BAX Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of -1.8% compared to Baxter International, Inc.'s net margin of 14.91%. Baxter International, Inc.'s return on equity of -4.83% beat Boston Scientific Corp.'s return on equity of 12.46%.

Baxter International, Inc. has a consensus price target of $23.67, signalling upside risk potential of 22.12%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 31.02%. Given that Boston Scientific Corp. has higher upside potential than Baxter International, Inc., analysts believe Boston Scientific Corp. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.612, which suggesting that the stock is 38.771% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.68%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Baxter International, Inc. quarterly revenues are $2.8B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Baxter International, Inc.'s net income of -$51M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while Boston Scientific Corp.'s PE ratio is 51.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.90x versus 7.41x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies, Inc. has a net margin of -1.8% compared to Baxter International, Inc.'s net margin of -2.7%. Baxter International, Inc.'s return on equity of -4.83% beat iRhythm Technologies, Inc.'s return on equity of -54.18%.

Baxter International, Inc. has a consensus price target of $23.67, signalling upside risk potential of 22.12%. On the other hand iRhythm Technologies, Inc. has an analysts' consensus of $218.60 which suggests that it could grow by 23.78%. Given that iRhythm Technologies, Inc. has higher upside potential than Baxter International, Inc., analysts believe iRhythm Technologies, Inc. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.612, which suggesting that the stock is 38.771% less volatile than S&P 500. In comparison iRhythm Technologies, Inc. has a beta of 1.099, suggesting its more volatile than the S&P 500 by 9.93%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.68%. iRhythm Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. iRhythm Technologies, Inc. pays out -- of its earnings as a dividend.

Baxter International, Inc. quarterly revenues are $2.8B, which are larger than iRhythm Technologies, Inc. quarterly revenues of $192.9M. Baxter International, Inc.'s net income of -$51M is lower than iRhythm Technologies, Inc.'s net income of -$5.2M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while iRhythm Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.90x versus 7.99x for iRhythm Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of -1.8% compared to Baxter International, Inc.'s net margin of 12.4%. Baxter International, Inc.'s return on equity of -4.83% beat Insulet Corp.'s return on equity of 18.92%.

Baxter International, Inc. has a consensus price target of $23.67, signalling upside risk potential of 22.12%. On the other hand Insulet Corp. has an analysts' consensus of $377.72 which suggests that it could grow by 30.87%. Given that Insulet Corp. has higher upside potential than Baxter International, Inc., analysts believe Insulet Corp. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.612, which suggesting that the stock is 38.771% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.68%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Baxter International, Inc. quarterly revenues are $2.8B, which are larger than Insulet Corp. quarterly revenues of $706.3M. Baxter International, Inc.'s net income of -$51M is lower than Insulet Corp.'s net income of $87.6M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while Insulet Corp.'s PE ratio is 83.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.90x versus 8.28x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of -1.8% compared to Baxter International, Inc.'s net margin of -8.49%. Baxter International, Inc.'s return on equity of -4.83% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.

Baxter International, Inc. has a consensus price target of $23.67, signalling upside risk potential of 22.12%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $24.81 which suggests that it could grow by 11.01%. Given that Baxter International, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Baxter International, Inc. is more attractive than Tandem Diabetes Care, Inc..

Baxter International, Inc. has a beta of 0.612, which suggesting that the stock is 38.771% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.685, suggesting its more volatile than the S&P 500 by 68.536%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.68%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

Baxter International, Inc. quarterly revenues are $2.8B, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Baxter International, Inc.'s net income of -$51M is lower than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.90x versus 1.48x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.